92.57
0.55%
-0.51
After Hours:
92.56
-0.010
-0.01%
Novartis AG ADR stock is currently priced at $92.57, with a 24-hour trading volume of 903.55K.
It has seen a -0.55% decreased in the last 24 hours and a -3.49% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $93.24 pivot point. If it approaches the $92.33 support level, significant changes may occur.
Novartis AG ADR Stock (NVS) Financials Data
Novartis AG ADR (NVS) Revenue 2024
NVS reported a revenue (TTM) of $51.01 billion for the quarter ending December 31, 2023, a +7.06% rise year-over-year.
Novartis AG ADR (NVS) Net Income 2024
NVS net income (TTM) was $14.85 billion for the quarter ending December 31, 2023, a +113.52% increase year-over-year.
Novartis AG ADR (NVS) Cash Flow 2024
NVS recorded a free cash flow (TTM) of $11.71 billion for the quarter ending December 31, 2023, a -2.43% decrease year-over-year.
Novartis AG ADR (NVS) Earnings per Share 2024
NVS earnings per share (TTM) was $7.10 for the quarter ending December 31, 2023, a +124.68% growth year-over-year.
Novartis AG ADR Stock (NVS) Latest News
Exploring Analyst Estimates for Novartis (NVS) Q1 Earnings, Beyond Revenue and EPS
Zacks Investment Research
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
The Motley Fool
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Benzinga
Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
Zacks Investment Research
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
The Motley Fool
Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate
Zacks Investment Research
About Novartis AG ADR
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; QIAGEN N.V.; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; and Conatus Pharmaceuticals Inc. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Cap:
|
Volume (24h):